Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
4 shares your portfolio should own
Healthcare Shares
2 blue chip healthcare shares you should own
⏸️ Investing
Top traders think the Australian Dollar is about to head lower
⏸️ Investing
Should you invest in these healthcare shares?
⏸️ Investing
How safe is your money in Cochlear Limited shares?
⏸️ Investing
3 shares I think could benefit from the Trump trade
⏸️ Investing
What's driving the Cochlear Limited share price to record highs?
⏸️ Investing
Why the Sirtex Medical Limited share price is falling
⏸️ Investing
3 shares to buy and hold forever
⏸️ Investing
3 healthy US Dollar ASX shares
⏸️ Investing
Hidden beneath the flat ASX stock market is a whole other world of opportunity
⏸️ Investing
The secret behind Amcor Limited's insane 69% return on equity
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
